AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.800
+0.050 (1.33%)
At close: Jul 3, 2025, 1:00 PM
3.830
+0.030 (0.79%)
After-hours: Jul 3, 2025, 4:57 PM EDT
AbCellera Biologics Stock Forecast
Stock Price Forecast
The 4 analysts that cover AbCellera Biologics stock have a consensus rating of "Strong Buy" and an average price target of $8.33, which forecasts a 119.21% increase in the stock price over the next year. The lowest target is $5 and the highest is $10.
Price Target: $8.33 (+119.21%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 16, 2025.
Analyst Ratings
The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $28 → $10 | Strong Buy | Maintains | $28 → $10 | +163.16% | May 16, 2025 |
| Keybanc | Keybanc | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +31.58% | Apr 16, 2025 |
| Benchmark | Benchmark | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 3, 2025 |
| Stifel | Stifel | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +163.16% | Feb 28, 2025 |
| Keybanc | Keybanc | Buy Maintains $5 → $4 | Buy | Maintains | $5 → $4 | +5.26% | Jan 8, 2025 |
Financial Forecast
Revenue This Year
20.63M
from 28.83M
Decreased by -28.46%
Revenue Next Year
34.65M
from 20.63M
Increased by 67.99%
EPS This Year
-0.68
from -0.55
EPS Next Year
-0.66
from -0.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 27.5M | 60.9M | 72.5M | ||
| Avg | 20.6M | 34.7M | 46.9M | ||
| Low | 15.7M | 22.4M | 30.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.6% | 195.2% | 109.1% | ||
| Avg | -28.5% | 68.0% | 35.4% | ||
| Low | -45.5% | 8.8% | -12.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.61 | -0.41 | -0.59 | ||
| Avg | -0.68 | -0.66 | -0.72 | ||
| Low | -0.74 | -0.79 | -0.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.